Conference Coverage

VIDEO: Consider comorbidities when preparing patients for systemic psoriasis therapy


 

EXPERT ANALYSIS AT SDEF LAS VEGAS DERMATOLOGY SEMINAR

– Clinicians should consider the increased risk for multiple comorbidities in their patients with psoriasis, Joel M. Gelfand, MD, said in a video interview at the Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

“These are patients who should undergo the type of age-appropriate screening that any patient should have,” including checks for blood pressure and diabetes, said Dr. Gelfand, professor of dermatology and epidemiology at the University of Pennsylvania, Philadelphia.

In terms of preparing for systemic psoriasis therapy, “there are lots of things we can do to lower the risk of having bad outcomes,” including age-appropriate cancer screening such as colonoscopy and mammography, he added. Vaccination is also an important strategy to help reduce the risk of potential side effects related to immunosuppression, he noted.

Dr. Gelfand disclosed relationships with multiple companies including AbbVie, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi, and Valeant.

SDEF and this news organization are owned by the same parent company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Birth outcomes unaffected by paternal immunosuppressive therapy
Psoriatic Arthritis Resource Center
Guselkumab achieves highest-ever response rates in psoriasis
Psoriatic Arthritis Resource Center
Secukinumab for psoriasis at 4 years: undiminished efficacy and safety
Psoriatic Arthritis Resource Center
Tildrakizumab for psoriasis scores high marks in phase III
Psoriatic Arthritis Resource Center
PsA bone loss measurement: A surrogate for radiographic progression?
Psoriatic Arthritis Resource Center
Close monitoring of psoriasis patients can delay PsA onset
Psoriatic Arthritis Resource Center
What good are biosimilars if patients won’t use them?
Psoriatic Arthritis Resource Center
Optimize anti–TNF-alpha therapy for psoriasis
Psoriatic Arthritis Resource Center
Study offers reassuring data on certolizumab use in pregnancy
Psoriatic Arthritis Resource Center
VIDEO: IL-23 inhibitors on the upswing
Psoriatic Arthritis Resource Center